세계의 혈우병 시장 보고서(2025년)

Hemophilia is a rare genetic disorder that affects the body's ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia.

The main types of hemophilia are hemophilia A, hemophilia B, hemophilia C and others. Hemophilia A refers to a genetic disorder characterized by a deficiency of a protein called clotting factor VIII (factor 8). The various treatments include replacement therapy, hemostatic agents, desmopressin, gene therapy and others. These are used by various end-users such as hospitals, clinics, home care settings and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hemophilia market research report is one of a series of new reports from The Business Research Company that provides hemophilia market statistics, including hemophilia industry global market size, regional shares, competitors with a hemophilia market share, detailed hemophilia market segments, market trends and opportunities and any further data you may need to thrive in the hemophilia industry. This hemophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemophilia market size has grown strongly in recent years. It will grow from $13.83 billion in 2024 to $14.98 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to government initiatives, increased number of hemophilic patients, rising diagnostic screening, increasing awareness about hemophilia treatments.

The hemophilia market size is expected to see strong growth in the next few years. It will grow to $20.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising research and development hemophilias, rising diagnostic screening, incremental healthcare spending, global access to treatment. Major trends in the forecast period include new drug launches and approvals, escalation in novel drug development, research and clinical trials, digital health solutions, advancements in treatment options.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper treatment access by increasing the cost of recombinant clotting factors and gene therapy vectors sourced from Spain and Switzerland, thereby risking bleeding complications and elevating rare disease expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the hemophilia market is expected to be primarily driven by the rising incidence of genetic abnormalities. Genetic abnormalities, also known as genetic mutations or genetic disorders, refer to alterations in an individual's DNA sequence that can lead to various health conditions and physical traits. Hemophilia treatment aims to mitigate or control bleeding episodes, reduce complications, and enhance the quality of life for individuals with genetic abnormalities. For instance, in June 2023, Gene People, a UK-based registered charity organization supporting individuals with genetic conditions, reported that one in every 25 children in the UK had a genetic disorder, affecting approximately 30,000 newborns and young children in the country, as well as more than 2.4 million children and adults annually. Consequently, the increasing occurrence of genetic abnormalities is a driving force behind the growth of the hemophilia market.

The growth of the hemophilia market is expected to be driven by increasing investment efforts in hemophilia care. These efforts encompass the allocation of financial resources, research and development initiatives, and healthcare infrastructure enhancements, all aimed at advancing the treatment, management, and overall well-being of individuals with hemophilia. By improving access to hemophilia treatment, particularly in developing regions, these initiatives and partnerships work to expand the patient pool and market size. For example, in September 2022, the National Hemophilia Foundation (NHF), a nonprofit organization based in the United States, introduced Pathway to Cures (P2C), an innovative venture philanthropy investment fund with an initial funding of $3.5 million. P2C is dedicated to achieving substantial and transformative advancements in the field of inheritable blood disorders, capitalizing on its team's expertise in blood disorder research and leveraging NHF's valuable connections with scientific research institutions and clinical experts. Therefore, the increasing investment efforts in hemophilia care are expected to be a driving force behind the growth of the hemophilia market.

Major companies operating in the hemophilia market are focusing on the development of innovative drugs, such as ALTUVIIIO, to maintain their competitive position. For example, in February 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, introduced ALTUVIIIO for the treatment of hemophilia. This medication received approval from the US-based government agency, the Food and Drug Administration (FDA). ALTUVIIIO offers the unique benefit of once-weekly dosing, providing regular to near-normal factor activity levels (above 40%) for most of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.

In February 2023, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical company specializing in hemophilia drugs, acquired Nimbus Therapeutics LLC for a sum of $4 billion. This strategic acquisition strengthens Takeda's late-stage pipeline and expands its portfolio, potentially broadening its impact on patients across multiple medical conditions. Nimbus Therapeutics LLC, a US-based pharmaceutical company, is engaged in the development and manufacturing of drugs for hemophilia.

Major companies operating in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Precision BioLogic Inc., Dimension Therapeutics, Chameleon Biosciences, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB.

North America was the largest region in the hemophilia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hemophilia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hemophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hemophilia market consists of revenues earned by entities by providing physical therapy, hemophilia centers (HTCs) and prophylactic care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemophilia market consists of sales of hemophilia drugs and medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemophilia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemophilia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemophilia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemophilia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
• 2) By Treatment: Replacement Therapy; Hemostatic Agents; Desmopressin; Gene Therapy; Other Treatments
• 3) By End-User: Hospitals; Clinics; Home Care Settings; Other End-Users
• Subsegments:
• 1) By Hemophilia A: Severe Hemophilia A; Moderate Hemophilia A; Mild Hemophilia A
• 2) By Hemophilia B: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B
• 3) By Hemophilia C: Severe Hemophilia C; Mild Hemophilia C
• 4) By Other Types: Acquired Hemophilia; Von Willebrand Disease
• Companies Mentioned: Kedrion S.p.A.; Chugai Pharmaceutical Co. Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Novo Nordisk A/S; Baxter International Inc.; CSL Limited; Biogen Inc.; Grifols S.A.; Octapharma AG; BioMarin Pharmaceutical Inc.; GC Pharma; Alnylam Pharmaceuticals Inc.; Bio Products Laboratory Ltd.; Sangamo Therapeutics Inc.; UniQure; Intellia tx; ProMetic BioSciences Ltd.; Precision BioLogic Inc.; Dimension Therapeutics; Chameleon Biosciences; Amarna therapeutics; HEMA Biologics LLC; Aptevo Therapeutics; Arcturus Therapeutics Inc.; Ferring Lakemedel AB
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hemophilia Market Characteristics

3. Hemophilia Market Trends And Strategies

4. Hemophilia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hemophilia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hemophilia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hemophilia Market Growth Rate Analysis
• 5.4. Global Hemophilia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hemophilia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hemophilia Total Addressable Market (TAM)

6. Hemophilia Market Segmentation

• 6.1. Global Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Other Types
• 6.2. Global Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Replacement Therapy
• Hemostatic Agents
• Desmopressin
• Gene Therapy
• Other Treatments
• 6.3. Global Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• Other End-Users
• 6.4. Global Hemophilia Market, Sub-Segmentation Of Hemophilia A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severe Hemophilia A
• Moderate Hemophilia A
• Mild Hemophilia A
• 6.5. Global Hemophilia Market, Sub-Segmentation Of Hemophilia B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severe Hemophilia B
• Moderate Hemophilia B
• Mild Hemophilia B
• 6.6. Global Hemophilia Market, Sub-Segmentation Of Hemophilia C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severe Hemophilia C
• Mild Hemophilia C
• 6.7. Global Hemophilia Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acquired Hemophilia
• Von Willebrand Disease

7. Hemophilia Market Regional And Country Analysis

• 7.1. Global Hemophilia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hemophilia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hemophilia Market

• 8.1. Asia-Pacific Hemophilia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hemophilia Market

• 9.1. China Hemophilia Market Overview
• 9.2. China Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hemophilia Market

• 10.1. India Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hemophilia Market

• 11.1. Japan Hemophilia Market Overview
• 11.2. Japan Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hemophilia Market

• 12.1. Australia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hemophilia Market

• 13.1. Indonesia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hemophilia Market

• 14.1. South Korea Hemophilia Market Overview
• 14.2. South Korea Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hemophilia Market

• 15.1. Western Europe Hemophilia Market Overview
• 15.2. Western Europe Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hemophilia Market

• 16.1. UK Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hemophilia Market

• 17.1. Germany Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hemophilia Market

• 18.1. France Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hemophilia Market

• 19.1. Italy Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hemophilia Market

• 20.1. Spain Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hemophilia Market

• 21.1. Eastern Europe Hemophilia Market Overview
• 21.2. Eastern Europe Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hemophilia Market

• 22.1. Russia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hemophilia Market

• 23.1. North America Hemophilia Market Overview
• 23.2. North America Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hemophilia Market

• 24.1. USA Hemophilia Market Overview
• 24.2. USA Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hemophilia Market

• 25.1. Canada Hemophilia Market Overview
• 25.2. Canada Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hemophilia Market

• 26.1. South America Hemophilia Market Overview
• 26.2. South America Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hemophilia Market

• 27.1. Brazil Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hemophilia Market

• 28.1. Middle East Hemophilia Market Overview
• 28.2. Middle East Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hemophilia Market

• 29.1. Africa Hemophilia Market Overview
• 29.2. Africa Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hemophilia Market Competitive Landscape And Company Profiles

• 30.1. Hemophilia Market Competitive Landscape
• 30.2. Hemophilia Market Company Profiles
  • 30.2.1. Kedrion S.p.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Hemophilia Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Novo Nordisk A/S
• 31.5. Baxter International Inc.
• 31.6. CSL Limited
• 31.7. Biogen Inc.
• 31.8. Grifols S.A.
• 31.9. Octapharma AG
• 31.10. BioMarin Pharmaceutical Inc.
• 31.11. GC Pharma
• 31.12. Alnylam Pharmaceuticals Inc.
• 31.13. Bio Products Laboratory Ltd.
• 31.14. Sangamo Therapeutics Inc.
• 31.15. UniQure

32. Global Hemophilia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hemophilia Market

34. Recent Developments In The Hemophilia Market

35. Hemophilia Market High Potential Countries, Segments and Strategies

• 35.1 Hemophilia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hemophilia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hemophilia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer